Year All2024202320222021 8/14/2024 Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders Read More 8/6/2024 Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Read More 6/20/2024 Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation Read More 5/14/2024 Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression Read More 5/7/2024 Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Read More 5/6/2024 Neumora Therapeutics to Participate in Upcoming Conferences in May Read More 4/15/2024 Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study Read More 3/13/2024 Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days Read More 3/7/2024 Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Read More 1/22/2024 Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer Read More
8/14/2024 Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders Read More
8/6/2024 Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Read More
6/20/2024 Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation Read More
5/14/2024 Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression Read More
5/7/2024 Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Read More
3/7/2024 Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Read More
